Literature DB >> 11321246

Prostate-specific antigen: current status.

M Lukes1, M Urban, M Záleský, R Zachoval, J Herácek, E Zdárský.   

Abstract

PSA is the most important of all tumor markers because it has significant applications in all aspects of the management of men with prostatic disease. Certainly, the most important utilization of PSA is for early detection of this most ubiquitous of all human neoplasms. In this article the authors describe the molecular forms of PSA and their characteristics, the factors influencing values of serum concentration of PSA, the problems of screening, and particularly the possibility to use PSA for detection of prostate carcinoma. A big problem in prostate carcinoma detection is the low specificity of PSA at the concentrations between 4-10 ng/ml, the so-called diagnostic gray zone, where the incidence of prostate carcinoma is only 25%. The authors evaluate the methods which make it possible to increase the sensitivity and/or specificity of PSA detection, such as PSA density, PSA density of the transition zone, PSA velocity, PSA doubling time, age-specific PSA, free PSA and, prospectively, the use of the RT-PCR technique.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11321246

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  5 in total

Review 1.  Patented prostate cancer biomarkers.

Authors:  Lisa Murphy; R William Watson
Journal:  Nat Rev Urol       Date:  2012-07-03       Impact factor: 14.432

2.  Role of Imaging in Prostate Cancer.

Authors:  Hossein Jadvar; Abass Alavi
Journal:  PET Clin       Date:  2009-04-01

Review 3.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

Review 4.  A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.

Authors:  Anmar M Nassir
Journal:  Saudi J Biol Sci       Date:  2020-02-10       Impact factor: 4.219

5.  The Marker State Space (MSS) method for classifying clinical samples.

Authors:  Brian P Fallon; Bryan Curnutte; Kevin A Maupin; Katie Partyka; Sunguk Choi; Randall E Brand; Christopher J Langmead; Waibhav Tembe; Brian B Haab
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.